| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2002;74:342-347
© 2002 The Society of Thoracic Surgeons
a Institute of Oncology, Assaf Harofeh Hospital, Zrifin, Israel
b Institute of Pathology, Assaf Harofeh Hospital, Zrifin, Israel
c Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
d Department of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
e Department of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
Accepted for publication April 24, 2002.
* Address reprint requests to Dr Cyjon, Institute of Oncology, Assaf Harofeh Hospital, Zrifin 70300, Israel
e-mail: acyjon{at}netscape.net
Background. Induction chemotherapy before operation is beneficial for patients with advanced locoregional non-small cell lung cancer. However, no optimal regimen has been established. This study assesses feasibility, response, resectability, and survival of chemotherapy followed by chemoradiation before operation in patients with non-small cell lung cancer.
Methods. Fifty-seven stage IIIA and selected IIIB patients with non-small cell lung cancer received 2/3 cycles of cisplatin and oral etoposide, followed in 3/4 weeks by chemoradiation with daily cisplatin before each radiation fraction. Patients achieving a resectable status underwent operation.
Results. Response to induction treatment was documented in 73%; 69% achieved a resectable status and 53% underwent operation. Median survival was 16 months. The 1-, 2-, and 3-year survival rates were 65%, 35% and 22%, respectively. There was no difference in survival between stage IIIA and IIIB disease. Myelotoxicity was moderate to severe (grade III/IV in 61% of patients). Three patients died of late complications of pneumonectomy.
Conclusions. Our presurgery chemotherapy and chemoradiation protocol yields high response and resectability rates, with moderate to severe myelotoxicity. Pneumonectomy is associated with a relatively high rate of late complications.
This article has been cited by other articles:
|
|
 |
|
  S. Gursoy, M. U Yapucu, A. Ucvet, S. Yazgan, O. Basok, and S. Ermete Fibrin Glue Administration to Support Bronchial Stump Line Asian Cardiovasc Thorac Ann, December 1, 2008; 16(6): 450 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fujita, N. Katakami, Y. Takahashi, K. Hirokawa, A. Ikeda, C. Tabata, T. Mio, and M. Mishima Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 896 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ohno, T. Utsumi, Y. Sasaki, and Y. Suzuki Re-evaluation of non-palpable scalene lymph node biopsy for the staging of non-small cell lung cancer Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 492 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jeremic, F. B. Zimmermann, and M. Molls Induction chemotherapy followed by concurrent chemoradiotherapy and operation in locally advanced non-small cell lung cancer Ann. Thorac. Surg., September 1, 2003; 76(3): 979 - 979. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
